期刊文献+

基因表达谱芯片在B细胞淋巴瘤分子分型、预后和治疗中的研究进展及应用前景 被引量:1

原文传递
导出
摘要 早期的淋巴瘤分类倚重于形态学或临床表现。近年来新技术的出现,特别是高通量的DNA技术,DNA芯片和基因表达谱在淋巴瘤中的研究取得了一系列成果,发现了不同淋巴瘤特征性的基因表达图谱,以及不同亚型淋巴瘤有不同的致癌途径及其与预后相关的表达谱,并初次尝试了淋巴瘤分子分型和分子病理诊断,为预后相关因子的建立及进一步指导临床治疗方案和个体化靶向治疗提供了科学依据。我们对基因表达谱在多种B细胞淋巴瘤(BCL),包括弥漫性大B细胞淋巴瘤(DLBCL)、原发性纵隔大B细胞淋巴瘤(PMBL)、Burkitt淋巴瘤、滤泡性淋巴瘤(FL)、
出处 《中华病理学杂志》 CAS CSCD 北大核心 2009年第11期785-789,共5页 Chinese Journal of Pathology
基金 基金项目:国家自然科学基金面上项目(30770918) 浙江省自然科学基金项目(Y205292) 教育部留学回国人员科研启动基金(2008-890) 浙江省人事厅留学人员科技活动择优资助项目(2007-324)
  • 相关文献

参考文献44

  • 1Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon : IARC Press, 2008:236.
  • 2Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol, 2001, 13(5) : 325-334.
  • 3Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-eelllymphoma identified by gene expression profiling. Nature, 2000, 403(6769): 503-511.
  • 4Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B- cell lymphoma. N Engl J Med, 2002, 346(25) : 1937-1947.
  • 5Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell- like diffuse large B cell lymphoma cells. J Exp Med, 2001,194 (12) : 1861-1874.
  • 6Ngo VN, Davis RE, Lamy L, et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature, 2006, 441 (7089) :106-110.
  • 7Lenz G, Davis RE, Ngo VN,et al. Oncogenic CARDll mutations in human diffuse large B cell lymphoma. Science, 2008,319 (5870) : 1676-1679.
  • 8Bea S, Zettl A, Wright G, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expressionbased survival prediction. Blood, 2005, 106(9) : 3183-3190.
  • 9Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A, 2008,105(36) :13520-13525.
  • 10Shaffer AL, Rosenwald A, Hurt EM, et al. Signatures of the immune response. Immunity,2001,15 ( 3 ) :375-385.

二级参考文献33

  • 1刘彤华.表皮生长因子受体家族与靶向性抗癌治疗[J].中华病理学杂志,2006,35(10):577-579. 被引量:21
  • 2张瑰红,施达仁,梁晓曼,侯景辉,康苏娅,朱卫东,李晓兵,邵云,陈丽荣,周燕.显色原位杂交和免疫组织化学检测乳腺癌HER2/neu基因状况和蛋白表达的对照性研究[J].中华病理学杂志,2006,35(10):580-583. 被引量:29
  • 3曾瑄,梁智勇,武莎斐,周炜洵,高洁,刘彤华.乳腺癌HER2蛋白表达阳性者的基因状态分析[J].中华病理学杂志,2006,35(10):584-588. 被引量:40
  • 4Dietel M, Sers C. Personalized medicine and development of targeted therapies : the upcoming challenge for diagnostic molecular pathology. A review. Virchows Arch, 2006, 448 (6) :744-755.
  • 5Watson MA, Perry A, Budhraja V, et al. Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas. Cancer Res, 2001,61 (5) : 1825-1829.
  • 6Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A, 2001,98(24) :13790-13795.
  • 7Giordano TJ, Shedden KA, Schwartz DR, et al. Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol, 2001, 159(4) :1231-1238.
  • 8van't Veer L J, Dai H, van de Vijver MJ, et al. Expression profiling predicts outcome in breast cancer. Breast Cancer Res, 2003,5( 1 ) :57-58.
  • 9Lesko LJ. Personalized medicine: elusive dream or imminent reality? Clin Pharmacol Ther, 2007,81 (6) :807-816.
  • 10Fierz W. Challenge of personalized health care: to what extent is medicine already individualized and what are the future trends? Med Sci Monit, 2004,10(5) :RA111-RA123.

共引文献16

同被引文献59

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部